Evidence map›Paper›PMID 33556085›Full record

Observational studyPloS one2021

Implementation of pre-exposure prophylaxis programme in Spain. Feasibility of four different delivery models.

Carlos Iniesta, Pep Coll, María Jesús Barberá, Miguel García Deltoro, Xabier Camino, Gabriela Fagúndez, Asunción Díaz, Rosa Polo, Spanish Working Group for PrEP

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05492565 (A Study to Evaluate Clinical Benefits and Drawbacks of Antiretroviral Drugs as Pre-exposure Prophylaxis to Prevent HIV Infection Under Real-life Conditions Among Persons Who Pursue High-risk Sexual Practices), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05492565 enrolling by invitationnot on this map

A Study to Evaluate Clinical Benefits and Drawbacks of Antiretroviral Drugs as Pre-exposure Prophylaxis to Prevent HIV Infection Under Real-life Conditions Among Persons Who Pursue High-risk Sexual Practices: The Seville HIV PrEP Cohort

Typeobservational_patient_registrySponsorHospitales Universitarios Virgen del RocíoRan2020 to 2030Enrolled500ConditionsHIV Infection Primary, Hepatitis, Viral, Human, Sexually Transmitted Infections, Excluding HIV and HepatitisArmsTenofovir Disoproxil Fumarate 300 MG Oral Tablet
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Carlos IniestaSpanish HIV/AIDS Research Network, National Centre of Epidemiology, Health Institute Carlos III, Madrid, Spain.ORCID 0000-0002-0928-2679
Pep CollBCN Checkpoint, Barcelona, España.
María Jesús BarberáSTI Unit Vall d´Hebron-Drassanes, Infectious Diseases Department, University Hospital Vall d'Hebron, Barcelona, Spain.
Miguel García DeltoroInfectious Disease Service, Consortium General University Hospital of Valencia, Valencia, Spain.ORCID 0000-0002-5969-1059
Xabier CaminoInfectious Disease Service, University Hospital of Donostia, San Sebastian, Spain.
Gabriela FagúndezNational AIDS Programme, Ministry of Health, Madrid, Spain.
Asunción DíazHIV and STI Surveillance Unit, National Centre of Epidemiology, Health Institute Carlos III, Madrid, Spain.ORCID 0000-0002-8309-4270
Rosa PoloNational AIDS Programme, Ministry of Health, Madrid, Spain.
Spanish Working Group for PrEP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPre-exposure prophylaxis (PrEP) is an effective and cost-effective strategy for HIV prevention. Spain carried out an implementation study in order to assess the feasibility of implementing PrEP programmes within its heterogeneous health system.

methodsObservational longitudinal study conducted on four different types of health-care setting: a community centre (CC), a sexually transmitted infections clinic (STIC), a hospital-based HIV unit (HBHIVU) and a hospital-based STI unit (HBSTIU). We recruited gay, bisexual and other men who have sex with men (GBSM) and transgender women at risk of HIV infections, gave them PrEP and monitored clinical, behavioural PrEP-related and satisfaction information for 52 weeks. We collected perceptions on PrEP implementation feasibility from health-care professionals participating in the study.

resultsA total of 321 participants were recruited, with 99.1% being GBMSM. Overall retention was 87.2% and it was highest at the CC (92.6%). Condom use decreased during the study period, while STIs did not increase consistently. The percentage of people who did not miss any doses of PrEP during the previous week remained at over 93%. No HIV seroconversions occurred. We observed overall decreases in GHB (32.5% to 21.8%), cocaine (27.5% to 21.4%), MDMA (25.7% to 14.3%), speed (11.4% to 5.7%) and mephedrone use (10.7% to 5.0%). The overall participant satisfaction with PrEP was 98.6%. Health-care professionals' perceptions of PrEP feasibility were positive, except for the lack of personnel.

conclusionsPrEP implementation is feasible in four types of health-care settings. Local specificities have to be taken into consideration while implementing PrEP.

Indexed as

AdultAnti-HIV AgentsFeasibility StudiesFemaleHealth PersonnelHIV InfectionsHumansLongitudinal StudiesMalePerceptionPre-Exposure ProphylaxisSafe SexSexual and Gender MinoritiesSexually Transmitted DiseasesSpainTransgender PersonsAnti-HIV Agents

Identifiers

PMID33556085
PMCPMC7870089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.